Fig. 1: Analysis of the HCV CoC in public hospitals in Madrid.

Pre-dialysis patients were omitted, given the high proportion of anti-HCV Ab and HCV–RNA testing (100.0%), out of those anti-HCV Ab positive for the latter, and low proportion of HCV–RNA-positive patients (0.0%). Category ‘Ever treated’ includes patients with ongoing and completed treatment. Denominator for ‘Anti-HCV Ab test’, ‘Anti-HCV Ab positive’ and ‘HCV-RNA test’ is the total n of patients of each corresponding group; ‘HCV-RNA positive’ is the n of patients who were tested for HCV-RNA of each corresponding group; ‘Eligible for treatment’ is the n of patients who tested positive for HCV–RNA of each corresponding group; ‘Ever treated’ is the n of patients who were eligible for treatment of each corresponding group; ‘SVR12 reached’ is the n of patients who completed treatment of each corresponding group; ‘LTFU/unknown SVR12’ is the n of patients who were ever treated of each corresponding group. Anti-HCV Ab HCV antibody, ALD advanced liver disease, CoC cascade of care, HCV hepatitis C virus, HHD hereditary haematological diseases, LTFU lost to follow-up, PWID people who inject drugs, SVR12 sustained virological response 12 weeks post treatment.